Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):1–19. doi: 10.1038/nrdp.2017.9
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, et al., Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548. doi: 10.1001/jamaoncol.2016.5688
   PubMed Web of Science ®Google Scholar
• Murray CJL, Aravkin AY, Zheng P, et al. 2019 risk factors collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223–1249. doi: 10.1016/S0140-6736(20)30752-2
   PubMed Web of Science ®Google Scholar
• Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45. doi: 10.1016/j.semcancer.2012.06.004
   PubMed Web of Science ®Google Scholar
• Zhang T, Xie J, Arai S, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7(45):73068–73079. doi: 10.18632/oncotarget.12230
   PubMedGoogle Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492. doi: 10.18632/oncotarget.2980
   PubMedGoogle Scholar
• Yan XQ, Ye MJ, Zou Q, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2023;S0923-7534(23):04003–04006. doi: 10.1016/j.annonc.2023.09.3108
   Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060. doi: 10.1016/j.lanepe.2021.100060
   PubMedGoogle Scholar
• Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations. BeiJing: China Market Press; 2020.
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528. doi: 10.1111/j.1524-4733.2004.75003.x
   PubMed Web of Science ®Google Scholar
• Thokala P, Ochalek J, Leech AA, et al. Cost-effectiveness thresholds: the past, the present and the future. PharmacoEconomics. 2018;36(5):509–522. doi: 10.1007/s40273-017-0606-1
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Gourzoulidis G. Does a standard cost-effectiveness threshold exist? The case of Greece. Value Health Reg Issues. 2023;36:18–26. doi: 10.1016/j.vhri.2023.02.006
   PubMedGoogle Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9–21. doi: 10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Andersson TM, Dickman PW, Eloranta S, et al. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11(1):96–106. doi: 10.1186/1471-2288-11-96
   PubMedGoogle Scholar
• Wang H, Wang Y, Li L, et al. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. Front Public Health. 2022;10:954264. doi: 10.3389/fpubh.2022.954264
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang Q, Sun J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer. 2018;6(1):124. doi: 10.1186/s40425-018-0440-9
   PubMedGoogle Scholar
• Ocran Mattila P, Ahmad R, Hasan SS, et al. Availability, affordability, access, and pricing of anti-cancer medicines in low-and middle-income countries: a systematic review of literature. Front Public Health. 2021;9:462. doi: 10.3389/fpubh.2021.628744
   Web of Science ®Google Scholar
• Shi G, Park SH, Ren H, et al. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. J Med Econ. 2018;21(12):1150–1158. doi: 10.1080/13696998.2018.1515769
   PubMed Web of Science ®Google Scholar
• Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98–101. doi: 10.1016/j.lungcan.2019.08.028
   PubMed Web of Science ®Google Scholar
• Remák E, Charbonneau C, Négrier S, et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26(24):3995–4000. doi: 10.1200/JCO.2007.13.2662
   PubMed Web of Science ®Google Scholar
• de Groot S, Redekop WK, Versteegh MM, et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res. 2018;7(1):115–124. doi: 10.1007/s11136-017-1704-4
   Google Scholar
• Amdahl J, Diaz J, Park J, et al. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):e340–354.
   PubMed Web of Science ®Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):61–68. doi: 10.1111/j.1524-4733.2009.00617.x
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989X12458348
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2018;16(3):e557–e562. doi: 10.1016/j.clgc.2018.02.006
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Re, Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol In press. 10.1016/j.eururo.2017.07.041: second-line treatment in metastatic renal cell carcinoma. Can immunotherapy be considered a cost-effective treatment? Eur Urol. 2018;73(3):e74. doi: 10.1016/j.eururo.2017.10.010
   PubMedGoogle Scholar
• Wang Y, Wang H, Yi M, et al. Cost-effectiveness of lenvatinib plus pembrolizumab or everolimus as first-line treatment of advanced renal cell carcinoma. Front Oncol. 2022;12:853901. doi: 10.3389/fonc.2022.853901
   PubMed Web of Science ®Google Scholar
• Chen J, Hu G, Chen Z, et al. Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China. Clin Drug Investig. 2019;39(10):931–938. doi: 10.1007/s40261-019-00820-6
   PubMed Web of Science ®Google Scholar